RESEARCH

• Project Objectives
• Work Plan
• Activities
• Identification of candidate genes in clinical samples
• Identification of candidate genes in preclinical model systems
• Validation in clinical samples
• Functional validation in preclinical model systems
• Identification of potential modulators of drug resistance
• Identification and validation of predictive markers of toxicity

Project Objectives

The main goals of the CHEMORES projects are to:

• Provide a robust set of clinically and functionally validated markers for clinical response to chemotherapy in melanoma and lung cancer. These may then be further developed to useful predictive tools that may help to identify patients who will benefit from a certain therapy in general oncological practice.

• Provide novel information on validated molecular mechanisms and pathways of chemotherapy resistance. This should increase the possibilities to develop new strategies to overcome resistance by targeting the key molecules involved in such pathways.
• Provide initial preclinical development of potential new modulators of chemotherapy resistance based on validated molecules and mechanisms of resistance.
• Provide new information on individual markers of toxicity caused by chemotherapy. This will be developed into tools that can be used to predict toxicity in individual patients. Such tools may be used to provide information of use for individualized dosing of chemotherapy, minimizing the risk of suffering severe toxicity while optimizing treatment efficacy.
• Provide clinical validation of novel preclinical animal tumour model systems. These can then be used in continued studies of chemosensitivity and resistance.